| scholarly article | Q13442814 |
| P50 | author | Nandita Guha-Thakurta | Q41599067 |
| Razelle Kurzrock | Q56614941 | ||
| P2093 | author name string | Sang Joon Shin | |
| Sarina A Piha-Paul | |||
| Michael Rytting | |||
| Tribhawan Vats | |||
| Joann Aaron | |||
| Eugenie Kleinerman | |||
| P2860 | cites work | Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase | Q22009924 |
| Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. | Q24540159 | ||
| Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy | Q29547379 | ||
| Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics | Q29617786 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| Medical management of brain tumor patients | Q31134402 | ||
| Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen | Q33392585 | ||
| The measurement of performance in childhood cancer patients | Q34050319 | ||
| Pten signaling in gliomas | Q34707865 | ||
| Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors | Q35112340 | ||
| Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. | Q35569214 | ||
| A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer | Q35584707 | ||
| VEGF as a key mediator of angiogenesis in cancer | Q36319024 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth | Q37275182 | ||
| Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. | Q40821386 | ||
| Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival | Q44407580 | ||
| Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma | Q44551425 | ||
| Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 | ||
| Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. | Q45006311 | ||
| Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. | Q46410598 | ||
| Bevacizumab plus irinotecan in recurrent glioblastoma multiforme | Q46942082 | ||
| Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. | Q48398636 | ||
| Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma | Q48761873 | ||
| Trends in childhood cancer incidence in the U.S. (1992-2004). | Q51111080 | ||
| Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. | Q55474277 | ||
| The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer | Q73734152 | ||
| Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition | Q80376810 | ||
| Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms | Q83588875 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| P304 | page(s) | 1939-1945 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | Anticancer Research | Q326290 |
| P1476 | title | Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus | |
| P478 | volume | 34 |
| Q52801683 | 18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors. |
| Q37058267 | Cancer prevention and therapy through the modulation of the tumor microenvironment |
| Q35788820 | Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis |
| Q64923739 | Embryonal Tumors of the Central Nervous System in Children: The Era of Targeted Therapeutics. |
| Q47133403 | Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. |
| Q46155460 | The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival |
Search more.